Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

Publication | Open Access

DOI Full Paper Access

243

Citations

References

2020

Year

Shaji Kumar, Susanna Jacobus, Adam D. Cohen, Matthias Weiss, Natalie S. Callander, Avina K. Singh, Terri L. Parker, Alexander Menter, Xuezhong Yang, Benjamin M. Parsons,

The Lancet Oncology

Hematological MalignancyOncologyMarrow TransplantationTransplantationImmunologyHematologyClinical TrialsMyeloid NeoplasiaMultiple MyelomaImmunotherapyMedicineCell TransplantationPhase 3Health Sciences